Robert W. Baird Issues Positive Forecast for Inspire Medical Systems (NYSE:INSP) Stock Price

Inspire Medical Systems (NYSE:INSP) had its price objective lifted by research analysts at Robert W. Baird from $54.00 to $59.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Robert W. Baird’s price target suggests a potential upside of 12.98% from the company’s previous close.

A number of other analysts also recently weighed in on the company. Bank of America downgraded Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price for the company. in a research report on Friday, May 22nd. Evercore downgraded shares of Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 price target on the stock. in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. lowered their price objective on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating for the company in a report on Tuesday, May 5th. Royal Bank Of Canada cut shares of Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a research note on Monday, June 15th. Finally, Wells Fargo & Company reduced their target price on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inspire Medical Systems currently has a consensus rating of “Hold” and a consensus price target of $69.06.

Inspire Medical Systems Trading Up 4.0%

INSP stock opened at $52.22 on Tuesday. The company’s 50 day moving average is $46.15 and its 200 day moving average is $55.17. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 11.63, a price-to-earnings-growth ratio of 5.08 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. During the same quarter in the previous year, the company posted $0.45 earnings per share. The company’s revenue was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, sell-side analysts forecast that Inspire Medical Systems will post 0.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. CWM LLC boosted its position in Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after buying an additional 242 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Inspire Medical Systems by 1,115.4% in the first quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after acquiring an additional 580 shares during the period. Havemeyer Place LP bought a new position in shares of Inspire Medical Systems during the fourth quarter valued at about $39,000. V Square Quantitative Management LLC bought a new position in shares of Inspire Medical Systems during the fourth quarter valued at about $40,000. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after purchasing an additional 205 shares during the period. 94.91% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates. Inspire reported adjusted earnings of $0.14 per share, compared with the consensus estimate of a $0.24 loss, while revenue of $200.6 million exceeded expectations of approximately $194.7 million. Inspire Medical Systems Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Full-year EPS guidance was raised above Wall Street expectations. Inspire now expects 2026 earnings of $1.05 to $1.45 per share, versus consensus of approximately $0.91. Revenue guidance of $835 million to $875 million brackets the $848.9 million analyst estimate. Inspire Medical Systems Announces Q2 Results and Raised Guidance
• Positive Sentiment: Management presented a strategic growth plan. The earnings release and conference call emphasized initiatives intended to support future adoption and expansion, giving investors a more constructive outlook for the company’s obstructive sleep apnea treatment business. Inspire Medical Systems Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Growth remains mixed. Quarterly revenue declined 7.6% from the prior year, and EPS fell from $0.45 to $0.14, although both results were better than analysts expected. Investors are therefore likely to focus on whether the new growth initiatives can restore sustained revenue growth.
• Negative Sentiment: The outlook still reflects execution risk. The revenue guidance range is relatively broad, and the midpoint is only modestly above current consensus, leaving the stock dependent on successful commercialization and broader procedure adoption.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.